- Home
- PRQR vs MDXH Comparison
PRQR vs MDXH Comparison
Compare PRQR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | MDXH |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | Netherlands | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.5M | 149.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRQR | MDXH |
|---|---|---|
| Price | $1.51 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $6.80 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 774.0K | 198.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $13.92 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.67 |
| 52 Week High | $3.10 | $5.33 |
Technical Indicators
Market Signals| Indicator | PRQR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 31.76 |
| Support Level | $1.34 | $1.96 |
| Resistance Level | $1.58 | $3.78 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 0.71 | 6.76 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.